Alkem Laboratories Ltd. has completed the acquisition of Occlutech, a leading specialist provider of minimally invasive cardiac devices, for an undisclosed amount. This corporate acquisition marks a significant strategic move for Alkem Laboratories, integrating Occlutech's advanced medical technology portfolio into its operations. Occlutech is dedicated to improving the quality of life for individuals with heart conditions through its innovative solutions.
Since its inception in 2003, Occlutech has focused on the development, production, and commercialization of first-class, minimally invasive cardiac implants. These devices address critical areas such as Congenital Heart Disease, Stroke Prevention, and Heart Failure, fulfilling a mission to enhance patients' lives and meet unmet medical needs globally. The company's products are distributed to hospitals and clinics across more than 80 countries, utilized by physicians in complex implantation procedures. Occlutech employs approximately 330 people, with its registration in Switzerland, manufacturing and R&D facilities in Germany and Türkiye, a global finance and distribution hub in Helsingborg, Sweden, and clinical operations in Minneapolis, U.S.
The acquisition of Occlutech by Alkem Laboratories Ltd. is a strategic step aimed at expanding Alkem's footprint within the medical technology sector and diversifying its product offerings. By bringing Occlutech's specialized cardiac device expertise under its umbrella, Alkem is poised to enter or strengthen its position in the high-growth market for minimally invasive cardiovascular interventions. This move is expected to leverage Occlutech's established global distribution network and advanced R&D capabilities.
Expected synergies from this acquisition include combining Alkem's operational strengths with Occlutech's specialized technology and market access. The integration is anticipated to accelerate the reach of Occlutech's life-improving cardiac implants to a broader patient base. The combined entity is set to enhance its capacity to innovate and deliver solutions that address critical cardiovascular health challenges worldwide, ultimately aiming to improve patient outcomes and quality of life on a larger scale.